摘要
目的:研究摩罗丹(浓缩丸)治疗慢性非萎缩性胃炎(CNAG)大鼠的疗效及作用机制,为摩罗丹(浓缩丸)在CNAG方面的药效学提供依据。方法:采用灌胃60%乙醇溶液、20 mmol/L去氧胆酸钠溶液与饮用低浓度氨水溶液联合饥饱失常的方法制备CNAG大鼠模型。通过测定胃液pH值、胃蛋白酶、血清胃动素、胃泌素水平评价摩罗丹(浓缩丸)对CNAG模型大鼠胃功能的改善作用,通过胃组织病理学检查,评价摩罗丹(浓缩丸)对CNAG模型大鼠胃黏膜炎症的改善作用。结果:2倍临床等效剂量西药阳性药枸橼酸铋钾颗粒以及摩罗丹(浓缩丸)高、中、低剂量均可不同程度改善CNAG模型大鼠的胃黏膜组织病理学情况(P<0.01)。摩罗丹(浓缩丸)高剂量组、枸橼酸铋钾颗粒组与模型组胃液pH值差异有统计学意义(P<0.05)。摩罗丹中剂量组、低剂量组胃动素表达水平与模型组差异有统计学意义(P<0.05、P<0.01)。结论:摩罗丹(浓缩丸)能够减轻CNAG大鼠的胃黏膜损伤,其机制可能与维持胃液pH值,调节胃动素有关,表明摩罗丹(浓缩丸)对CNAG有较好的治疗作用,并对胃黏膜有修复和保护作用。
Objective:To study the efficacy and mechanism of Moluodan(concentrated pills) in the treatment of chronic non-atrophic gastritis(CNAG) in rats, and provide a pharmacodynamic research basis for Moluodan(concentrated pills) in CNAG.Methods:The CNAG rat model was prepared by gavage of 60% ethanol solution and 20 mmol/L sodium deoxycholate solution and drinking low-concentration ammonia solution combined with starvation-satiation method.The improvement of gastric function of CNAG rats by Moluodan(concentrated pills) was evaluated by measuring the pH value and pepsin level of gastric juice and serum motilin(MTL) and gastrin(GAS) level.And the improvement of Moluodan(concentrated pills) on gastric mucosal inflammation of CNAG rats was evaluated through gastric histopathological examination.Results:The positive drug(Bismuth Potassium Citrate Granules, JYSBJ,two-fold clinically equivalent dose),and Moluodan high-dose(MLD-H),medium-dose(MLD-M),and low-dose(MLD-L) all improved the gastric mucosal lesions of CNAG rats to varying degrees(P<0.01).The pH value of gastric juice in the MLD-H,JYSBJ and model groups were different(P<0.05).The expression levels of MTL in the MLD-M and MLD-L groups were different from those in the model group(P<0.05,P<0.01).Conclusion:The effect of Moluodan(concentrated pill) on gastric mucosal injury of CNAG rats might be related to the maintenance of gastric pH and the regulation of MTL,which indicated that Moluodan(concentrated pill) had a desirable therapeutic effect on CNAG rats, and could repair and protect the gastric mucous membrane.
作者
于泽玥
郝莉雨
陈红映
李宗源
孙建辉
霍海如
李洪梅
YU Zeyue;HAO Liyu;CHEN Hongying;LI Zongyuan;SUN Jianhui;HUO Hairu;LI Hongmei(Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《世界中医药》
CAS
2022年第16期2307-2311,共5页
World Chinese Medicine
基金
国家自然科学基金项目(81891010)
科技部科技基础性工作专项(2015FY111500-012)
山东省重点研发计划项目(2017CXG1301)。